Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting tumor angiogenesis (1). The gene discussed is KDR; the disease is neoplasm.